Acquisition momentum With Innovis Pharma recently acquired by PharmaPath, there is an immediate opportunity to engage in cross-sell of generic and specialty products, leveraging integrated manufacturing capabilities and expanded distribution channels to accelerate market reach.

Integrated capabilities The combined strengths in research and development, manufacturing, and commercial excellence create a compelling case for joint product launches, co-branded initiatives, and accelerated time-to-market for new therapies and medical devices.

Greek market focus As a leading Greek pharmaceutical company with a patient-centric approach, there is potential to deepen partnerships with hospitals and clinics in Attikí and greater Greece for generics, specialty brands, and dietary supplements.

Diverse portfolio A portfolio spanning generics, specialty brands, medical devices, and specialized food supplements opens multiple sales avenues—target hospital procurement, private clinics, and wholesale distributors seeking diversified product lines.

Growth potential Revenue in the low-to-mid single-digit millions and scalable infrastructure post-acquisition suggest opportunities to propose value-added services such as supply chain optimization, digital marketing for product launches, and data-driven market access strategies.